Clonal blood mutations common in breast cancer may sharply raise heart failure risk after anthracyclines, urging better screening and personalized cardio-oncology care.
Hanna Jensen
Advertisement
Articles by Hanna Jensen
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Capivasertib Combo Earns FDA Approval in PTEN-Deficient Metastatic HSPC
2
FDA Approves Adjuvant Belzutifan/Pembrolizumab in Clear Cell RCC Post Nephrectomy
3
VT-EBV-N Yields Durable Disease-Free Survival in Pretreated ENKTL
4
Anbenitamab Regimen Meets Phase 3 End Points in HER2+ Breast Cancer
5